Vertical Tabs

General Information

This Model was autogenerated from the "Quick Submit" tool.

Model ID

3DPX-015007

Category

Small Molecules

Keyword(s)

Talazoparib, 1207456-01-6, BMN-673, BMN 673, BMN673, Talazoparib (BMN 673), UNII-9QHX048FRV, (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one, LT-673, 9QHX048FRV

Talazoparib was approved by the FDA for use in germline BRCA mutated, HER2 negative, locally advanced or metastatic breast cancer on October 16, 2018 under the trade name Talzenna. Talzenna was granted approval based on the results of the EMBRACA trial in which talazoparib resulted in a mean 8.6 months progression-free survival time versus physician's choice chemotherapy which resulted in 5.6 months progression-free survival.

PubChem CID

135565082

Molecular Weight

380.4 g/mol

Molecular Formula

CN₁C(=NC=N₁)[C@@H]₂[C@H](NC₃=CC(=CC₄=C₃C₂=NNC₄=O)F)C₅=CC=C(C=C₅)F

IUPAC

(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one

CAS

1207456-01-6

Documentation

PubChem 2D Image